SCHEMBL3170343

SCHEMBL3170343

CCc1cc(N)c(C(=O)OC)c(CC)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 1/20 0.42
AGTR2 P50052 1/20 0.42
ALDH1A1 P00352 5/20 0.40
MAPT P10636 4/20 0.40
HPGD P15428 3/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40
DHFR P00374 4/20 0.36
KDM4E B2RXH2 4/20 0.36
GAA P10253 3/20 0.36
HSD17B10 Q99714 3/20 0.36
TSHR P16473 2/20 0.36
ALOX15 P16050 1/20 0.36
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRB1 P18505 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11081950 0.84 ALDH1A1 (0.43) ALDH1A1MAPTHPGDMEN1CYP1A2
SCHEMBL9430191 0.83 AGTR1 (0.43) AGTR1AGTR2ALDH1A1MAPTHPGD
SCHEMBL9430194 0.83 CYP3A4 (0.44) AGTR1AGTR2ALDH1A1MAPTHPGD
SCHEMBL7274895 0.82 GABRP (0.44) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL7286429 0.82 NOS3 (0.38) AGTR1AGTR2ALDH1A1HPGDMEN1
SCHEMBL1424213 0.74 NQO2 (0.43) ALDH1A1MAPTHPGDCYP1A2KDM4E
SCHEMBL7277168 0.73 KDM4E (0.43) ALDH1A1HPGDMEN1KMT2AKDM4E
SCHEMBL9431184 0.73 AGTR1 (0.43) AGTR1AGTR2ALDH1A1ALOX15
SCHEMBL24566358 0.71 NQO2 (0.47) ALDH1A1MAPTKDM4EGAAHSD17B10
SCHEMBL8570997 0.71 GAA (0.41) ALDH1A1MAPTHPGDKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100010035-A1 Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors TORRENT PHARMACEUTICALS LTD. (IN) 2010-01-14 US disclosed
US-20100010035-A1 Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors TORRENT PHARMACEUTICALS LTD. (IN) 2010-01-14 US disclosed
US-20100010035-A1 Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors TORRENT PHARMACEUTICALS LTD. (IN) 2010-01-14 US disclosed
CN-101437818-A Novel Dual Acting Receptor Antagonists (DARA) for AT1 and ETA receptors TORRENT PHARMACEUTICALS LTD (IN) 2009-05-20 CN disclosed
EP-1996588-A1 NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS Torrent Pharmaceuticals Ltd (IN) 2008-12-03 EP disclosed
WO-2007100295-A1 NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS TORRENT PHARMACEUTICALS LTD (IN) 2007-09-07 WO disclosed
WO-2007100295-A1 NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS TORRENT PHARMACEUTICALS LTD (IN) 2007-09-07 WO disclosed
EP-0516392-B1 Naphthyridine derivatives as angiotensin II inhibitors ASTRAZENECA AB (SE) 2001-08-29 EP disclosed
EP-0520724-B1 Angiotensin II antagonists ZENECA LTD (GB) 1995-09-20 EP disclosed
US-5387592-A Angiotensin converting enzyme inhibitors, calcium channel blockers, diuretics and adrenergic blocking agents IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1995-02-07 US disclosed
US-5281613-A Heterocyclic ring substituted benzofuran, benzothiofuran, or indole derivative IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1994-01-25 US disclosed
WO-1993024501-A1 PHOSPHORUS CONTAINING HETEROCYCLIC COMPOUNDS AS ANGIOTENSINS ANTAGONISTS ZENECA LIMITED (GB) 1993-12-09 WO disclosed
WO-1993024487-A1 NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS ANGIOTENSIN-II-ANTAGONISTS ZENECA LIMITED (GB) 1993-12-09 WO disclosed
US-5236937-A Treating hypertension, congestive heart failure IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-08-17 US disclosed
US-5217976-A Hypotensive agents, congestive heart failure IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-06-08 US disclosed
EP-0539066-A1 Heterocyclic compounds useful as angiotensin II antagonists ZENECA LIMITED (GB) 1993-04-28 EP disclosed
EP-0520723-A1 Angiotensin II antagonists IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-12-30 EP disclosed
EP-0520724-A1 Angiotensin II antagonists ZENECA LIMITED (GB) 1992-12-30 EP disclosed
EP-0516392-A2 Naphthyridine derivatives as angiotensin II inhibitors ZENECA LIMITED (GB) 1992-12-02 EP disclosed
EP-0499415-A1 Pyridine and quinoline derivatives, processes for their manufacture and their use as angiotensin II antagonists ZENECA LIMITED (GB) 1992-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010035-A1 Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors EDNRA, EDNRB, AGTR1 AGTR1 3/4885AGTR2 4/4885ALDH1A1 892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.